You are here

Cancer Discov DOI:10.1158/2159-8290.CD-19-1390

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer.

Publication TypeJournal Article
Year of Publication2020
AuthorsWander, SA, Cohen, O, Gong, X, Johnson, GN, Buendia-Buendia, JE, Lloyd, MR, Kim, D, Luo, F, Mao, P, Helvie, K, Kowalski, KJ, Nayar, U, Waks, AG, Parsons, SH, Martinez, R, Litchfield, LM, Ye, XS, Yu, C, Jansen, VM, Stille, JR, Smith, PS, Oakley, GJoseph, Chu, QS, Batist, G, Hughes, ME, Kremer, JD, Garraway, LA, Winer, EP, Tolaney, SM, Lin, NU, Buchanan, SG, Wagle, N
JournalCancer Discov
Date Published2020 May 13

Mechanisms driving resistance to CDK4/6 inhibitors in HR+ breast cancer have not been clearly defined. Whole exome sequencing of 59 tumors with CDK4/6i exposure revealed multiple candidate resistance mechanisms including RB1 loss, activating alterations in AKT1, RAS, AURKA, CCNE2, ERBB2, and FGFR2, and loss of ER expression. In vitro experiments confirmed that these alterations conferred CDK4/6i resistance. Cancer cells cultured to resistance with CDK4/6i also acquired RB1, KRAS, AURKA, or CCNE2 alterations, which conferred sensitivity to AURKA, ERK, or CHEK1 inhibition. Three of these activating alterations-in AKT1, RAS, and AURKA-have not to our knowledge been previously demonstrated as mechanisms of resistance to CDK4/6 inhibitors in breast cancer preclinically or in patient samples. Together, these eight mechanisms were present in 66% of resistant tumors profiled and may define therapeutic opportunities in patients.


Alternate JournalCancer Discov
PubMed ID32404308